STOCK TITAN
  1. Home
  2. Sec-filings
  3. LXEO
  4. [Form 4] Lexeo Therapeutics, Inc. Insider Trading Activity

Lexeo Therapeutics (LXEO) CFO sells shares for RSU taxes

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. (LXEO) reported that its Chief Financial Officer, Louis Edward Tamayo, sold 4,117 shares of common stock on 2026-08-18 at a weighted average price of $4.91 per share. According to the company’s disclosure, this sale represents shares sold to cover tax obligations arising from the release of restricted stock units. After this transaction, Tamayo directly holds 92,907 shares of Lexeo common stock, including 78,415 Restricted Stock Units.

Positive

  • None.

Negative

  • None.
Insider Tamayo Louis Edward
Role Chief Financial Officer
Sold 4,117 shs ($20K)
Type Security Shares Price Value
Sale Common Stock F1, F2, F3 4,117 $4.9071 $20K
Holdings After Transaction: Common Stock — 92,907 shares (Direct)
Footnotes (3)
  1. F1. Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").
  2. F2. This transaction was executed in multiple trades at prices ranging from $4.83 to $5.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  3. F3. Includes 78,415 Restricted Stock Units.
Shares sold 4,117 shares Common Stock sale on 2026-08-18 by CFO Louis Edward Tamayo
Weighted average sale price $4.9071 per share Weighted average of multiple trades ranging from $4.83 to $5.01
Shares held after transaction 92,907 shares Direct holdings of CFO Louis Edward Tamayo following the reported sale
Restricted Stock Units included 78,415 Restricted Stock Units Portion of the CFO’s post-transaction holdings that are RSUs
Net insider share change 4,117 shares Net-sell shares reported in transaction summary for this filing
Restricted Stock Units financial
"Includes 78,415 Restricted Stock Units."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
tax obligations financial
"Represents a sale to cover tax obligations on the release of restricted stock units"

FAQ

What insider transaction did Lexeo Therapeutics (LXEO) report for CFO Louis Edward Tamayo?
Lexeo Therapeutics reported that CFO Louis Edward Tamayo sold 4,117 shares of common stock on 2026-08-18. The company states this sale was made to cover tax obligations related to the release of restricted stock units.

At what price were the Lexeo Therapeutics (LXEO) shares sold by the CFO?
The reported sale price was a weighted average of $4.91 per share, based on trades from $4.83 to $5.01. Lexeo notes that full trade-by-trade pricing details are available upon request from the reporting person.

How many Lexeo Therapeutics (LXEO) shares does the CFO hold after this transaction?
After the transaction, CFO Louis Edward Tamayo directly holds 92,907 shares of Lexeo common stock. This figure includes 78,415 Restricted Stock Units (RSUs) as part of his reported equity position in the company.

What is the nature of the Lexeo Therapeutics (LXEO) CFO’s reported share sale?
Lexeo reports the CFO’s transaction as a sale of 4,117 shares of common stock. A footnote clarifies that the purpose was to cover tax obligations on vested restricted stock units, rather than an independent discretionary sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tamayo Louis Edward
(Last)(First)(Middle)
C/O LEXEO THERAPEUTICS, INC.
345 PARK AVENUE SOUTH, FLOOR 6
(Street)
NEW YORK NEW YORK 10010
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/18/2026S(1)4,117D$4.9071(2)92,907(3)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").
2. This transaction was executed in multiple trades at prices ranging from $4.83 to $5.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. Includes 78,415 Restricted Stock Units.
/s/ Youjin Choi, Attorney-in-Fact08/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR